Immutep will halt the Phase III TACTI-004 trial after an IDMC interim analysis found futility in ~756 first-line advanced/metastatic NSCLC patients without EGFR/ALK/ROS1 alterations treated with eftilagimod alfa (soluble LAG-3 protein/MHC II agonist) + pembrolizumab + chemotherapy vs placebo combo. Shares fell as much as 88% following the disclosure, and the company said it is reviewing available data to understand the outcome.

Why It Matters To Oncology

• It’s a high-profile late-stage setback for a LAG-3 pathway approach positioned as an immunotherapy intensifier on top of PD-1 blockade and chemo in front-line NSCLC.

• The stop raises questions about translatability from the earlier TACTI-002 signal (median OS 25 months reported in PD-L1 TPS ≥1% first-line NSCLC) to a registrational setting with dual primary endpoints (PFS and OS).

• Analysts flagged that absent trial-conduct issues, the mechanism of action may come under increased scrutiny for this indication and regimen.

The Financials

• Immutep shares cratered as much as 88% on the news.

• Management said ending TACTI-004 early extends cash runway beyond Q2 2027 (the prior guidance).

• Cash was boosted by a $20M upfront payment from Dr. Reddy’s for rights to eftilagimod alfa outside North America, Europe, Japan and China.

What They're Saying

• CEO Marc Voigt: “We are very disappointed and surprised with the outcome…in light of [eftilagimod alfa's] performance in every other clinical trial.”

• Voigt: “We are currently conducting a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the programme.”

• Citizens JMP: “Unless something happened with the conduct of the clinical trial, we believe the mechanism of action for [eftilagimod alfa] will now be called into question.”

What's Next

• Company review of interim data to identify whether specific subgroups, biomarkers, or operational factors could explain the futility call.

• Readouts/updates on the broader pembrolizumab combination strategy, including the partnered TACTI-003 head and neck program, which has already shown lacklustre Phase II results.

• Portfolio and partnering decisions as Immutep reassesses development priorities for eftilagimod alfa after a Phase III stop.